# Hangzhou Nuohui Health Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hangzhou-nuohui-health-technology-co

- Industry: Healthcare
- Headquarters: Hangzhou, China
- Website: www.newhorizonbio.com
- Total disclosed funding: $156M
- Latest round: Series E (Jul 10, 2020)
- Investors on record: 22

## About

Hangzhou Nuohui Health Technology Co., Ltd. specializes in innovative cancer screening solutions, focusing on early detection through advanced diagnostic technologies and home testing products.Founded in 2015, Hangzhou Nuohui Health Technology Co., Ltd. is dedicated to developing and providing early cancer screening solutions. The company is headquartered in Hangzhou, China. The founders Yeqing Zhu and Yiyou Chen have led the company through various growth phases. As of February 18, 2021, the company completed an IPO, raising HKD 2.0421 billion.NuoHui Health offers a range of diagnostic products, including liquid biopsy tests that facilitate non-invasive cancer detection. These products are designed to improve patient outcomes by enabling early intervention and are targeted towards healthcare providers and individual consumers. The company intends to expand its offerings internationally, addressing a growing demand for reliable cancer screening solutions.In the most recent year, 2021, NuoHui Health reported a revenue of HKD 32,978,182.30 and an EBITDA of HKD -476,696,641.10. The company's revenue is primarily generated through direct-to-consumer sales and partnerships with healthcare facilities, focusing on diagnostic tests and home testing kits.Following its IPO on February 18, 2021, in which it raised HKD 2.0421 billion, Hangzhou Nuohui Health Technology Co., Ltd. plans to utilize these funds to support the development of new diagnostic products and expand into international markets. The company is targeting expansion into North America and Europe, aiming for growth in these regions by 2023.

## Funding rounds

- Series E, Jul 10, 2020, $30M — OrbiMed Advisors, Qiming Venture Partners, Lilly Asia Ventures, CR Capital, Rock Springs Capital, Cormorant Asset Management, Octagon Capital Advisors
- Series D, Apr 21, 2020, $20M — Qiming Venture Partners, SB China Venture Capital, OmniScience Capital, Exome Asset Management
- Series C, May 24, 2019, $66M — Legend Capital, SB China Venture Capital, YiMei Capital, Majuven, DUMAC, Acorn Pacific Ventures, VMS Asset Management, Sherpa Healthcare Partners
- Series B, Aug 9, 2017, $20M — Legend Capital, Qiming Venture Partners, SB China Venture Capital, Zhejiang Pudu Technology
- Series A, May 27, 2016, $20M — Legend Capital, SB China Venture Capital, Zhejiang Pudu Technology, Beijing Tianyi Huirong Investment Management
- Angel, Mar 1, 2016 — Acorn Campus Ventures, Haibang Venture, The Linhui Fund

## Investors

- Acorn Campus Ventures (https://capitalatlas.ai/funds/acorn-campus-ventures) — Angel
- Haibang Venture — Angel
- The Linhui Fund (https://capitalatlas.ai/funds/the-linhui-fund) — Angel
- Legend Capital — Series A, Series B, Series C
- SB China Venture Capital (https://capitalatlas.ai/funds/sb-china-venture-capital) — Series A, Series B, Series C, Series D
- Zhejiang Pudu Technology — Series A, Series B
- Beijing Tianyi Huirong Investment Management — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B, Series D, Series E
- YiMei Capital (https://capitalatlas.ai/funds/yimei-capital) — Series C
- Majuven (https://capitalatlas.ai/funds/majuven) — Series C
- DUMAC — Series C
- Acorn Pacific Ventures (https://capitalatlas.ai/funds/acorn-pacific-ventures) — Series C
- VMS Asset Management (https://capitalatlas.ai/funds/vms-asset-management) — Series C
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series C
- OmniScience Capital — Series D
- Exome Asset Management — Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series E
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series E
- CR Capital (https://capitalatlas.ai/funds/cr-capital) — Series E
- Rock Springs Capital — Series E
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series E
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series E